Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 70, No 1 (2019)
Original paper
Submitted: 2018-03-15
Accepted: 2018-07-11
Published online: 2018-09-21
View PDF Download PDF file
Get Citation

The importance of combined NGS and MLPA genetic tests for differential diagnosis of maturity onset diabetes of the young

Jovana Komazec1, Vera Zdravkovic23, Silvija Sajic23, Maja Jesic23, Marina Andjelkovic1, Sonja Pavlovic1, Milena Ugrin1
DOI: 10.5603/EP.a2018.0064
·
Pubmed: 30259503
·
Endokrynol Pol 2019;70(1):28-36.
Affiliations
  1. Institute of Molecular Genetics and Genetic Engineering, Belgrade, Serbia and Montenegro
  2. Division of endocrinology, University Children’s Hospital, Belgrade, Serbia and Montenegro
  3. School of Medicine, University of Belgrade, Belgrade, Serbia and Montenegro

open access

Vol 70, No 1 (2019)
Original Paper
Submitted: 2018-03-15
Accepted: 2018-07-11
Published online: 2018-09-21

Abstract

Introduction: Maturity onset diabetes of the young (MODY) is a rare form of monogenic diabetes. Being clinically and genetically heterogeneous, it is often misdiagnosed as type 1 or type 2 diabetes, leading to inappropriate therapy. MODY is caused by a single gene mutation. Thirteen genes, defining 13 subtypes, have been identified to cause MODY. A correct diagnosis is important for the right therapy, prognosis, and genetic counselling.
Material and methods: Twenty-nine unrelated paediatric patients clinically suspected of having MODY diabetes were analysed using TruSight One panel for next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) assay.
Results: In this study we identified variants in MODY genes in 22 out of 29 patients (75.9%). Using two genetic tests, NGS and MLPA, we detected both single nucleotide variants and large deletions in patients. Most of the patients harboured a variant in the GCK gene (11/22), followed by HNF1B (5/22). The rest of the variants were found in the NEUROD1 and HNF1A genes. We identified one novel variant in the GCK gene: c.596T>C, p.Val199Ala. The applied genetic tests excluded the suspected diagnosis of MODY in two patients and revealed variants in other genes possibly associated with the patient’s clinical phenotype.
Conclusions: In our group of MODY patients most variants were found in the GCK gene, followed by variants in HNF1B, NEUROD1, and HNF1A genes. The combined NGS and MLPA-based genetic tests presented a comprehensive approach for analysing patients with suspected MODY diabetes and provided a successful differential diagnosis of MODY subtypes.

Abstract

Introduction: Maturity onset diabetes of the young (MODY) is a rare form of monogenic diabetes. Being clinically and genetically heterogeneous, it is often misdiagnosed as type 1 or type 2 diabetes, leading to inappropriate therapy. MODY is caused by a single gene mutation. Thirteen genes, defining 13 subtypes, have been identified to cause MODY. A correct diagnosis is important for the right therapy, prognosis, and genetic counselling.
Material and methods: Twenty-nine unrelated paediatric patients clinically suspected of having MODY diabetes were analysed using TruSight One panel for next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) assay.
Results: In this study we identified variants in MODY genes in 22 out of 29 patients (75.9%). Using two genetic tests, NGS and MLPA, we detected both single nucleotide variants and large deletions in patients. Most of the patients harboured a variant in the GCK gene (11/22), followed by HNF1B (5/22). The rest of the variants were found in the NEUROD1 and HNF1A genes. We identified one novel variant in the GCK gene: c.596T>C, p.Val199Ala. The applied genetic tests excluded the suspected diagnosis of MODY in two patients and revealed variants in other genes possibly associated with the patient’s clinical phenotype.
Conclusions: In our group of MODY patients most variants were found in the GCK gene, followed by variants in HNF1B, NEUROD1, and HNF1A genes. The combined NGS and MLPA-based genetic tests presented a comprehensive approach for analysing patients with suspected MODY diabetes and provided a successful differential diagnosis of MODY subtypes.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

MODY; NGS; MLPA; differential diagnosis

About this article
Title

The importance of combined NGS and MLPA genetic tests for differential diagnosis of maturity onset diabetes of the young

Journal

Endokrynologia Polska

Issue

Vol 70, No 1 (2019)

Article type

Original paper

Pages

28-36

Published online

2018-09-21

Page views

4032

Article views/downloads

2091

DOI

10.5603/EP.a2018.0064

Pubmed

30259503

Bibliographic record

Endokrynol Pol 2019;70(1):28-36.

Keywords

MODY
NGS
MLPA
differential diagnosis

Authors

Jovana Komazec
Vera Zdravkovic
Silvija Sajic
Maja Jesic
Marina Andjelkovic
Sonja Pavlovic
Milena Ugrin

References (62)
  1. Lachance CH. Practical Aspects of Monogenic Diabetes: A Clinical Point of View. Can J Diabetes. 2016; 40(5): 368–375.
    CrossRefPubMed
  2. Colclough K, Saint-Martin C, Timsit J, et al. Clinical utility gene card for: Maturity-onset diabetes of the young. Eur J Hum Genet. 2014; 22(9).
    CrossRefPubMed
  3. Shields B, Colclough K. Towards a systematic nationwide screening strategy for MODY. Diabetologia. 2017; 60(4): 609–612.
    CrossRefPubMed
  4. Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf). 2011; 75(4): 422–426.
    CrossRefPubMed
  5. Steele AM, Shields BM, Wensley KJ, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014; 311(3): 279–286.
    CrossRefPubMed
  6. Shepherd M, Miles S, Jones J, et al. Differential diagnosis: Identifying people with monogenic diabetes. Journal of Diabetes Nursing. 2010; 14: 342–347.
  7. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010; 53(12): 2504–2508.
    CrossRefPubMed
  8. Bingham C, Hattersley AT. Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant. 2004; 19(11): 2703–2708.
    CrossRefPubMed
  9. Kleinberger JW, Pollin TI. Undiagnosed MODY: Time for Action. Curr Diab Rep. 2015; 15(12): 110.
    CrossRefPubMed
  10. Nyunt O, Wu JY, McGown IN, et al. Investigating maturity onset diabetes of the young. Clin Biochem Rev. 2009; 30(2): 67–74.
    PubMed
  11. Gao R, Liu Y, Gjesing AP, et al. Evaluation of a target region capture sequencing platform using monogenic diabetes as a study-model. BMC Genet. 2014; 15: 13.
    CrossRefPubMed
  12. Johansson S, Irgens H, Chudasama KK, et al. Exome sequencing and genetic testing for MODY. PLoS One. 2012; 7(5): e38050.
    CrossRefPubMed
  13. Ellard S, Lango Allen H, De Franco E, et al. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia. 2013; 56(9): 1958–1963.
    CrossRefPubMed
  14. Ellard S, Thomas K, Edghill EL, et al. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia. 2007; 50(11): 2313–2317.
    CrossRefPubMed
  15. Edghill EL, Stals K, Oram RA, et al. HNF1B deletions in patients with young-onset diabetes but no known renal disease. Diabet Med. 2013; 30(1): 114–117.
    CrossRefPubMed
  16. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009; 30(11): 1512–1526.
    CrossRefPubMed
  17. Lorini R, Klersy C, d'Annunzio G, et al. Italian Society of Pediatric Endocrinology and Diabetology (ISPED) Study Group. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care. 2009; 32(10): 1864–1866.
    CrossRefPubMed
  18. Pruhova S, Dusatkova P, Sumnik Z, et al. Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations. Pediatr Diabetes. 2010; 11(8): 529–535.
    CrossRefPubMed
  19. Estalella I, Rica I, Perez de Nanclares G, et al. Spanish MODY Group. Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clin Endocrinol (Oxf). 2007; 67(4): 538–546.
    CrossRefPubMed
  20. Hattersley AT. Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med. 1998; 15(1): 15–24.
    CrossRefPubMed
  21. Carmody D, Naylor RN, Bell CD, et al. GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016; 53(5): 703–708.
    CrossRefPubMed
  22. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008; 4(4): 200–213.
    CrossRefPubMed
  23. Bansal V, Gassenhuber J, Phillips T, et al. Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals. BMC Med. 2017; 15(1): 213.
    CrossRefPubMed
  24. Murphy R. Monogenic diabetes and pregnancy. Obstet Med. 2015; 8(3): 114–120.
    CrossRefPubMed
  25. Bellanné-Chantelot C, Clauin S, Chauveau D, et al. Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diabetes. 2005; 54(11): 3126–3132.
    PubMed
  26. Ulinski T, Lescure S, Beaufils S, et al. Renal phenotypes related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. J Am Soc Nephrol. 2006; 17(2): 497–503.
    CrossRefPubMed
  27. Chen YZ, Gao Q, Zhao XZ, et al. Systematic review of TCF2 anomalies in renal cysts and diabetes syndrome/maturity onset diabetes of the young type 5. Chin Med J (Engl). 2010; 123(22): 3326–3333.
    PubMed
  28. Thirumalai A, Holing E, Brown Z, et al. A case of hepatocyte nuclear factor-1β (TCF2) maturity onset diabetes of the young misdiagnosed as type 1 diabetes and treated unnecessarily with insulin. J Diabetes. 2013; 5(4): 462–464.
    CrossRefPubMed
  29. Raaijmakers A, Corveleyn A, Devriendt K, et al. Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. Nephrol Dial Transplant. 2015; 30(5): 835–842.
    CrossRefPubMed
  30. Fauser S, Munz M, Besch D. Further support for digenic inheritance in Bardet-Biedl syndrome. J Med Genet. 2003; 40(8): e104.
    PubMed
  31. Losekoot M, Haarloo C, Ruivenkamp C, et al. Analysis of missense variants in the PKHD1-gene in patients with autosomal recessive polycystic kidney disease (ARPKD). Hum Genet. 2005; 118(2): 185–206.
    CrossRefPubMed
  32. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat. 2006; 27(9): 854–869.
    CrossRefPubMed
  33. Owen KR, Thanabalasingham G, James TJ, et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care. 2010; 33(9): 1919–1924.
    CrossRefPubMed
  34. Bellanné-Chantelot C, Lévy DJ, Carette C, et al. French Monogenic Diabetes Study Group. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J Clin Endocrinol Metab. 2011; 96(8): E1346–E1351.
    CrossRefPubMed
  35. Pruhova S, Ek J, Lebl J, et al. Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha. Diabetologia. 2003; 46(2): 291–295.
    CrossRefPubMed
  36. Anuradha S, Radha V, Deepa R, et al. A prevalent amino acid polymorphism at codon 98 (Ala98Val) of the hepatocyte nuclear factor-1alpha is associated with maturity-onset diabetes of the young and younger age at onset of type 2 diabetes in Asian Indians. Diabetes Care. 2005; 28(10): 2430–2435.
    PubMed
  37. Malecki MT, Skupien J, Gorczynska-Kosiorz S, et al. Renal malformations may be linked to mutations in the hepatocyte nuclear factor-1alpha (MODY3) gene. Diabetes Care. 2005; 28(11): 2774–2776.
    PubMed
  38. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. 1999; 23(3): 323–328.
    CrossRefPubMed
  39. Kristinsson SY, Thorolfsdottir ET, Talseth B, et al. MODY in Iceland is associated with mutations in HNF-1alpha and a novel mutation in NeuroD1. Diabetologia. 2001; 44(11): 2098–2103.
    CrossRefPubMed
  40. Gonsorcíková L, Průhová S, Cinek O, et al. Autosomal inheritance of diabetes in two families characterized by obesity and a novel H241Q mutation in NEUROD1. Pediatr Diabetes. 2008; 9(4 Pt 2): 367–372.
    CrossRefPubMed
  41. Szopa M, Ludwig-Galezowska AH, Radkowski P, et al. A family with the Arg103Pro mutation in the NEUROD1 gene detected by next-generation sequencing - Clinical characteristics of mutation carriers. Eur J Med Genet. 2016; 59(2): 75–79.
    CrossRefPubMed
  42. Liu L, Furuta H, Minami A, et al. A novel mutation, Ser159Pro in the NeuroD1/BETA2 gene contributes to the development of diabetes in a Chinese potential MODY family. Mol Cell Biochem. 2007; 303(1-2): 115–120.
    CrossRefPubMed
  43. Hansen L, Jensen JN, Urioste S, et al. NeuroD/BETA2 gene variability and diabetes: no associations to late-onset type 2 diabetes but an A45 allele may represent a susceptibility marker for type 1 diabetes among Danes. Danish Study Group of Diabetes in Childhood, and the Danish IDDM Epidemiology and Genetics Group. Diabetes. 2000; 49(5): 876–878.
    PubMed
  44. Thomas ERa, Brackenridge A, Kidd J, et al. Diagnosis of monogenic diabetes: 10-Year experience in a large multi-ethnic diabetes center. J Diabetes Investig. 2016; 7(3): 332–337.
    CrossRefPubMed
  45. Bonfig W, Hermanns S, Warncke K, et al. GCK-MODY (MODY 2) Caused by a Novel p.Phe330Ser Mutation. ISRN Pediatr. 2011; 2011: 676549.
    CrossRefPubMed
  46. Cullen KS, Matschinsky FM, Agius L, et al. Susceptibility of glucokinase-MODY mutants to inactivation by oxidative stress in pancreatic β-cells. Diabetes. 2011; 60(12): 3175–3185.
    CrossRefPubMed
  47. Johansen A, Ek J, Mortensen HB, et al. Half of clinically defined maturity-onset diabetes of the young patients in Denmark do not have mutations in HNF4A, GCK, and TCF1. J Clin Endocrinol Metab. 2005; 90(8): 4607–4614.
    CrossRefPubMed
  48. Codner E, Rocha A, Deng L, et al. Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus. Pediatr Diabetes. 2009; 10(6): 382–388.
    CrossRefPubMed
  49. Borowiec M, Antosik K, Fendler W, et al. Novel glucokinase mutations in patients with monogenic diabetes — clinical outline of GCK-MD and potential for founder effect in Slavic population. Clin Genet. 2012; 81(3): 278–283.
    CrossRefPubMed
  50. Sakura H, Eto K, Kadowaki H, et al. Structure of the human glucokinase gene and identification of a missense mutation in a Japanese patient with early-onset non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1992; 75(6): 1571–1573.
    CrossRefPubMed
  51. Weinert LS, Silveiro SP, Giuffrida FMA, et al. Three unreported glucokinase (GCK) missense mutations detected in the screening of thirty-two Brazilian kindreds for GCK and HNF1A-MODY. Diabetes Res Clin Pract. 2014; 106(2): e44–e48.
    CrossRefPubMed
  52. Beer NL, Osbak KK, van de Bunt M, et al. Insights into the pathogenicity of rare missense GCK variants from the identification and functional characterization of compound heterozygous and double mutations inherited in cis. Diabetes Care. 2012; 35(7): 1482–1484.
    CrossRefPubMed
  53. Papadimitriou DT, Willems PJ, Bothou C, et al. A novel heterozygous mutation in the glucokinase gene is responsible for an early-onset mild form of maturity-onset diabetes of the young, type 2. Diabetes Metab. 2015; 41(4): 342–343.
    CrossRefPubMed
  54. Gloyn AL. Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat. 2003; 22(5): 353–362.
    CrossRefPubMed
  55. Shakya P, Aryal S, Aryal R, et al. Occurrence of amino acid mutation (Ala98Val) of HNF1α in association with type II diabetes. J Nepal Health Res Counc. 2014; 12(27): 116–118.
    PubMed
  56. Yamagata K, Nammo T, Moriwaki M, et al. Mutation P291fsinsC in the transcription factor hepatocyte nuclear factor-1alpha is dominant negative. Diabetes. 1998; 47(8): 1231–1235.
    PubMed
  57. Yamada S, Nishigori H, Onda H, et al. Identification of mutations in the hepatocyte nuclear factor (HNF)-1 alpha gene in Japanese subjects with IDDM. Diabetes. 1997; 46(10): 1643–1647.
    PubMed
  58. Wang H, Antinozzi PA, Hagenfeldt KA, et al. Molecular targets of a human HNF1 alpha mutation responsible for pancreatic beta-cell dysfunction. EMBO J. 2000; 19(16): 4257–4264.
    CrossRefPubMed
  59. Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int. 2011; 80(7): 768–776.
    CrossRefPubMed
  60. Bingham C, Bulman MP, Ellard S, et al. Mutations in the hepatocyte nuclear factor-1beta gene are associated with familial hypoplastic glomerulocystic kidney disease. Am J Hum Genet. 2001; 68(1): 219–224.
    CrossRefPubMed
  61. Weber S, Moriniere V, Knüppel T, et al. Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. J Am Soc Nephrol. 2006; 17(10): 2864–2870.
    CrossRefPubMed
  62. Yorifuji T, Fujimaru R, Hosokawa Y, et al. Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus. Pediatr Diabetes. 2012; 13(1): 26–32.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl